InsidersTradesSigma
Total declarations
Company
▲ Purchases (3 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
3
Disclosed sells
0
T+90 hit rate
67%
T+90 mean return
+5.1%
Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Discover the complete record of transactions filed by John Sundy, Independent Director. Director active across 1 company, notably SANOFI. Aggregated, 3 disclosures have been logged. Breakdown: 3 buys · 0 sell. Total volume traded: €130k. Activity tracked since 21 June 2024. The latest transaction was filed on 2 April 2025 (Acquisition). Regulator: AMF. The full history is openly available.
Declarations3 total
1,000 shares@ US$55.02539.8% of flowAmerican Depositary sharesNasdaq, Inc.2025DD1029322
Ideal exit: 28 Dec 2025 (T+270)
887 shares@ €46.942730.1% of flowAmerican Depositary sharesNasdaq, Inc.2024DD983022
Ideal exit: 18 Mar 2025 (T+270)
887 shares@ US$46.942730.1% of flowAmerican Depositary sharesNasdaq, Inc.2024DD983315
Ideal exit: 18 Mar 2025 (T+270)
3 of 3 declarations
About John Sundy
John Sundy has served as an independent director of Sanofi since April 2024 and is a member of the company’s Scientific Committee, where his scientific background and senior management experience provide valuable insight into research and innovation priorities. A physician-scientist by training, he is currently Chief Medical Officer and Head of Research and Development at Seismic Therapeutic, an immunology-focused company leveraging machine learning to accelerate drug discovery. He is also an Adjunct Professor of Medicine in the Division of Rheumatology and Immunology at Duke University School of Medicine. Before entering the biopharmaceutical industry in 2014, John Sundy spent many years at Duke University as a tenured faculty member. That combination of academic research and industry leadership is a defining strength of his career. From 2014 to 2021, he held several executive positions in biotechnology and pharmaceutical companies, including Senior Vice President at Gilead Sciences and Chief Medical Officer at Pandion Therapeutics. In these roles, he was involved in clinical strategy, portfolio development, medical leadership, and the translation of scientific innovation into development programs with clear operational discipline. His core expertise lies in immunology, rheumatology, allergy/immunology, and the clinical development of novel therapies. He also serves on the board of Neutrolis, Inc., the Childhood Arthritis and Rheumatology Research Alliance, and the Steering Committee of the NIH Immune Tolerance Network, reflecting a long-standing commitment to translational research and precision medicine ecosystems. Sundy earned a B.S. in Biology from Bucknell University and an M.D./Ph.D. from Hahnemann University, with a specialization in immunology, and completed clinical training in rheumatology and allergy/immunology at Duke. At Sanofi, Sundy contributes to oversight of the group’s scientific direction, with a particular focus on emerging trends, new therapeutic opportunities, and R&D investment decisions. His profile is especially relevant for a global biopharmaceutical leader whose growth depends on a robust research pipeline, clinical rigor, and sustained scientific innovation.
